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Abstract
Background: Cigarette smoking and chemical occupational exposure are the main known risk
factors for bladder transitional cell carcinoma (TCC). Oxidative DNA damage induced by
carcinogens present in these exposures requires accurate base excision repair (BER). The XRCC1
protein plays a crucial role in BER by acting as a scaffold for other BER enzymes. Variants in the
XRCC1 gene might alter protein structure or function or create alternatively spliced proteins
which may influence BER efficiency and hence affect individual susceptibility to bladder cancer.
Recent epidemiological studies have shown inconsistent associations between these
polymorphisms and bladder cancer. To clarify the situation, we conducted a comprehensive
analysis of 14 XRCC1 polymorphisms in a case-control study involving more than 1100 subjects.
Results: We found no evidence of an association between any of the 14 XRCC1 polymorphisms
and bladder cancer risk. However, we found carriage of the variant Arg280His allele to be
marginally associated with increased bladder cancer risk compared to the wild-type genotype
(adjusted odds ratio [95% confidence interval], 1.50 [0.98–2.28], p = 0.06). The association was
stronger for current smokers such that individuals carrying the variant 280His allele had a two to
three-fold increased risk of bladder cancer compared to those carrying the wildtype genotype (p
= 0.09). However, the evidence for gene-environment interaction was not statistically significant (p
= 0.45).
Conclusion: We provide no evidence of an association between polymorphisms in XRCC1 and
bladder cancer risk, although our study had only limited power to detect the association for low
frequency variants, such as Arg280His.
Background
Bladder cancer is the fourth most common malignancy in
Europeans [1]. Tobacco smoking and occupational expo-
sure to chemicals are two well established risk factors
[2,3]. Associated carcinogens damage DNA, and failure of
accurate repair can result in mutations which may trigger
carcinogenesis.
Interindividual variability in DNA repair capability (DRC)
is an important factor influencing an individual's cancer
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risk [4]. DNA repair gene polymorphisms may contribute
to this variation [5]. XRCC1 is an essential DNA repair
gene involved in base excision repair (BER) [6]. Spontane-
ous chromosome aberrations and deletions are seen in
XRCC1 mutant cells (EM9), and XRCC1 knock out (-/-)
mice are embryonic lethal [7,8].
The XRCC1 gene exhibits polymorphic variations, includ-
ing three common single nucleotide polymorphisms
(SNPs) that result in amino acid substitutions in exon 7
(Arg194Trp), exon 9 (Arg280His) and exon 10
(Arg399Gln). These nonconservative amino acid altera-
tions may influence DRC by altering the protein-protein
interactions between XRCC1 and other BER proteins. The
Arg399Gln variant was found to be associated with several
phenotypic alterations, including higher levels of sister
chromatid exchange [9], aflatoxin B1-DNA adducts, glyc-
ophorin A mutations [10] and polyphenol DNA adducts
[11], although other data found no adverse effect on DRC
[12]. One study suggested the 194Trp variant has
increased DRC [10]. Functional studies showed that the
Arg280His variant has reduced cellular BER efficiency
[13,14].
Epidemiological studies have shown significant associa-
tions between the Arg399Gln variant and various cancers
(reviewed by Goode et al. [15]), but in bladder cancer the
results have been inconsistent [16-18]. A recent meta-
analysis of 38 case-control studies by Hu et al. [19] con-
cluded that the Arg194Trp variant had a protective effect
on cancer risk, while individuals carrying the Arg280His
variant allele had increased cancer risk compared to those
with the wildtype genotypes (odds ratio [95% confidence
intervals], 1.19 [1.00–1.42]).
In addition to coding SNPs, non-coding XRCC1 polymor-
phisms may also affect DRC by altering the splice site or
transcription efficiency. Recently, Hao et al. [20] discov-
ered a novel T-77C polymorphism (rs3213245) in the
XRCC1 gene which contributes to diminished promoter
activity and increased risk of non-small cell lung cancer.
In the present study, we performed a comprehensive anal-
ysis of 14 potentially functional polymorphisms (coding
and non coding) in XRCC1 to investigate their associa-
tions with bladder cancer. Furthermore, we constructed
XRCC1 haplotypes and assessed interactions with smok-
ing and occupational exposure.
Results
Subject characteristics
Demographic details for each subject have been described
previously [21]. The majority of subjects were Caucasian
(98.6%) with no difference in mean age (cases 72.8 years;
controls 71.9 years). There was no significant difference in
mean age of community and hospital controls (p = 0.19)
and no difference in smoking or occupational exposure
rates. There were however more men in the hospital group
(P < 0.001) because of an attempt to obtain a similar over-
all sex ratio to the cases. Cases were more likely than con-
trols to be smokers (78% vs. 64%, p < 0.001), male
(70.9% vs. 65.5%, p = 0.05), have previous occupational
exposure (27.4% vs. 16.8%, p < 0.001) and a positive
family history of bladder cancer (4.8% vs. 2.2%, p = 0.02).
Genotyping
The genotyping success rate was 95.0% (range 90.1 to
98.1%). The control genotype distributions were all in
Hardy-Weinberg equilibrium. Hospital and community
control genotypes only differed in one polymorphism,
Gln632Gln at the 5% level (minor allele frequency 0.48
vs.0.41, p = 0.04), consistent with random variation given
the number of polymorphisms examined so the two con-
trol groups were combined to increase the study power.
We found no variant allele for Val72. The remaining pol-
ymorphisms exhibited strong linkage disequilibrium
(LD) (Table 1). The crude and adjusted odds ratio for all
14 XRCC1 polymorphisms and bladder cancer risk are
shown in Table 2. No polymorphism showed association
with bladder cancer risk at the 5% significance level,
although individuals carrying the 280His variant allele
had a marginally significant increased risk of bladder TCC
compared to those carrying the homozygote wildtype gen-
otype (adjusted OR [95% CI], 1.50 [0.98–2.28], p = 0.06).
Gene-environment interactions
Individuals were stratified by smoking status (non-smok-
ers, and ex- and current smokers) and occupational expo-
sure (exposure and no exposure). Current smokers
carrying the 280His variant allele were associated with a
non-significant two to three-fold increased bladder TCC
risk compared to those carrying the homozygous wildtype
genotype (adjusted OR [95%CI], 2.52 [0.87–7.31], p =
0.09) (Table 3). We found no evidence of gene-environ-
ment interactions between Arg194Trp, Arg280His or
Arg399Gln and tobacco smoking (p-values for departure
from multiplicative joint effect = 0.32, 0.45 and 0.25
respectively). Similarly, there was no evidence of interac-
tion between occupational status and any of the three
non-synonymous polymorphisms (p-values for departure
from multiplicative joint effect = 0.33, 0.40 and 0.12
respectively).
Haplotype analysis
We selected the three coding polymorphisms with amino
acid substitutions previously commonly investigated,
namely Arg194Trp, Arg280His and Arg399Gln to con-
struct XRCC1 haplotypes. Four common haplotypes were
estimated to account for over 99% of all haplotypesBMC Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2156/8/13
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(Table 4). There was no significant difference in haplotype
frequency between cases and controls (p = 0.60).
Discussion
To date, this is the most comprehensive investigation on
the association between XRCC1 polymorphisms and
bladder TCC risk. We chose to study one gene comprehen-
sively rather than studying a small number of SNPs in
multiple genes, as others have done, for a number of rea-
sons. Firstly, non-coding SNPs in the promoter region, 3'
or 5'UTR or putative splice sites have been shown to influ-
ence DNA repair capacity [20]. Secondly this approach
allows for construction and analysis of haplotypes and
provides data on linkage disequilibrium between SNPs in
the gene. We found none of the 14 XRCC1 polymor-
phisms was associated with bladder cancer risk. Our
results on the Arg399Gln were consistent with other stud-
ies in bladder cancer [17,18]. Although our study was
larger and had sufficient power, our results did not sup-
port the finding of Kelsey et al. [16] that the variant
399Gln was protective against bladder cancer. We also
found no association between Arg194Trp and bladder
cancer risk which is consistent with Wu et al. [18].
Recently, Hao et al. [20] in 1024 Chinese lung cancer
patients and 1118 controls, showed that a 5'UTR SNP (T-
77C, rs3213245), is associated with an increased risk of
lung cancer, with OR for carriage of the variant allele of
1.46 (95% CI 1.18–1.82) compared to wildtype genotype.
In functional studies the C allele-containing promoter
had reduced transcriptional activity. We, however,
showed no association for this SNP and increased bladder
cancer risk.
Our data provided borderline evidence of association
between Arg280His and bladder TCC with an estimated
50% increase in risk to individuals carrying the 280His
variant (adjusted OR [95%CI], 1.50 [0.98–2.28]) but this
study only had limited power (55%) to detect association
with this variant. The association between XRCC1
Arg280His and an increased risk of bladder cancer is bio-
logically plausible [13,14]. Takanami et al. [14] showed
that the XRCC1 Arg280His variant protein is defective in
its efficient localization to a damaged DNA site and thus
impaired the cellular BER efficiency. Furthermore, the
recent meta-analysis by Hu et al. [19] also found the
280His variant to be associated with increased cancer risk.
However, the only previous bladder cancer study by Stern
et al. [22] (235 cases and 213 controls) found no associa-
tion. Our discrepant findings may be explained by false
positive or false negative results, or the different popula-
tions studied.
Table 1: The linkage disequilibrium (LD) between all 14 XRCC1 polymorphisms
No Polymo
rphisms
12345 6 789 10 11 12 13 14
1E X 1 -
1139 D' 
(r2)
0.20 
(0.13)
2E X 1 -
1128
0.82 
(0.57)
0.22 
(0.13)
3E X 1 -
900
0.92 
(0.30)
0.98 
(0.39)
0.41 
(0.22)
4 EX-128 0.89 
(0.27)
0.95 
(0.35)
1 
(0.93)
0.42 
(0.22)
5 EX-52 1 (0.01) 1 (0.01) 1 (0.02) 0.68 
(0.02)
0.03 
(0.02)
6 Val72Al
a
N/A N/A N/A N/A N/A 0 
(0.03)
7 Arg194
Trp
1 (0.02) 1 (0.02) 0.97 
(0.04)
0.97 
(0.04)
1 (0) N/A 0.06 
(0.12)
8 IVS7-33 0.04 (0) 0.05 (0) 0.06 (0) 0.06 (0) 0.15 (0) N/A 0.13 (0) 0.46 
(0.11)
9 Pro206
Pro
0.89 
(0.24)
0.96 
(0.32)
1 
(0.83)
0.97 
(0.83)
0.39 
(0.01)
N/A 0.98 
(0.05)
0.06 (0) 0.44 
(0.26)
10 Arg280
His
0.65 (0) 0.93 
(0.01)
0.79 
(0.02)
0.74 
(0.02)
1 (0) N/A 1 (0) 1 (0.04) 0.70 
(0.02)
0.04 
(0.10)
11 Arg399
Gln
0.87 
(0.11)
0.93 
(0.14)
1 (0.39) 0.96 
(0.39)
0.04 (0) N/A 1 (0.04) 0.08 (0) 0.99 
(0.47)
1 (0.03) 0.37 
(0.23)
12 Gln632
Gln
0.86 
(0.24)
0.95 
(0.32)
0.99 
(0.84)
0.91 
(0.77)
1 (0.02) N/A 0.91 
(0.04)
0.06 (0) 0.97 
(0.90)
0.61 
(0.01)
1 (0.45) 0.56 
(0.29)
13 EX17-
123
0.69 
(0.01)
0.76 
(0.01)
0.86 
(0.03)
0.92 
(0.03)
1 (0) N/A 1 (0) 0 (0) 0.94 
(0.04)
0.82 (0) 0.98 
(0.03)
0.88 
(0.04)
0.06 
(0.13)
14 EX17-
127
0.69 
(0.03)
0.75 
(0.04)
0.95 
(0.33)
0.96 
(0.32)
1 (0.01) N/A 0.77 
(0.01)
0.08 (0) 1 (0.30) 1 (0.01) 1 (0.16) 0.99 
(0.31)
0.11 (0) 0.21 
(0.09)
Values in bold italics represent the observed followed by estimated (in round bracket) control minor allele frequencies from public databases.
* LD is presented in pairwise D' followed by r2 in round bracket.
N/A = Not available because of no pairwise variant genotypes in rare polymorphisms.
Values in bold are polymorphisms in high LD (D' ≥ 0.90and r2 ≥ 0.80).BMC Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2156/8/13
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Table 2: The association between the 14 XRCC1 polymorphisms and bladder cancer risk
Polymorphisms* Genotypes Controls, n (%) Cases, n (%) aOR (95% CI) P value
EX1-1139 C/C 328 (61.5) 295 (59.0) 1.00 reference
rs2682586 C/T 187 (35.1) 181 (36.2) 1.07 (0.82–1.39) 0.62
Promoter T/T 18 (3.4) 24 (4.8) 1.42 (0.74–2.71) 0.29
T allele freq. 0.209 0.229
EX1-1128 rs2682585 C/C C/T 319 (60.3) 189 (35.7) 287 (59.1) 177 (36.4) 1.00 1.05 (0.81–1.37) reference 0.71
Promoter T/T 21 (4.0) 22 (4.5) 1.15 (0.61–2.18) 0.66
T allele freq. 0.218 0.227
EX1-900 -/- 196 (35.5) 173 (34.0) 1.00 reference
rs3213239 -/+ 267 (48.2) 256 (50.3) 1.04 (0.79–1.36) 0.79
Promoter +/+ 91 (16.4) 80 (15.7) 1.02 (0.71–1.48) 0.91
+ allele freq. 0.405 0.409
EX-128 C/C 187 (33.6) 174 (32.8) 1.00 reference
rs3213245 C/T 275 (49.4) 266 (50.2) 1.00 (0.76–1.31) 0.97
5'UTR T/T 94 (16.9) 90 (17.0) 1.06 (0.74–1.52) 0.76
T allele freq. 0.416 0.421
EX-52 C/C 548 (97.2) 520 (97.6) 1.00 reference
rs2307187 C/T 16 (2.8) 13 (2.4) 0.91 (0.43–1.92) 0.80
5'UTR T/T 0 0 NC NC
T allele freq. 0.014 0.012
Val72Ala C/C 562 (100) 521 (100) 1.00 reference
rs25496 C/T 0 0 NC NC
Exon 3 T/T 0 0 NC NC
T allele freq. 0 0
Arg194Trp C/C 498 (88.6) 476 (89.0) 1.00 reference
rs1799782 C/T 61 (10.9) 56 (10.4) 0.95 (0.64–1.41) 0.81
Exon 6 T/T 3 (0.5) 3 (0.6) 1.01 (0.19–5.23) 0.99
C/T + T/T 64 (11.4) 59 (11.0) 0.95 (0.65–1.40) 0.81
T allele freq. 0.060 0.058
IVS7-33 C/C 518 (91.7) 484 (89.6) 1.00 referenceBMC Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2156/8/13
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rs1799780 C/T 47 (8.3) 55 (10.1) 1.30 (0.85–1.97) 0.22
Intron 7 T/T 0 (0) 1 (0.2) ∞ NC
C/T + T/T 47 (8.3) 56 (10.4) 1.33 (0.88–2.01) 0.18
T allele freq. 0.042 0.053
Pro206Pro G/G 170 (31.2) 162 (31.4) 1.00 reference
rs915927 G/A 270 (49.5) 260 (50.5) 0.96 (0.73–1.28) 0.80
Exon 7 A/A 105 (19.3) 93 (18.1) 0.91 (0.64–1.31) 0.63
A allele freq. 0.440 0.433
Arg280His G/G 516 (92.1) 456 (88.9) 1.00 reference
rs25489 G/A 41 (7.3) 54 (10.5) 1.52 (0.98–2.34) 0.06
Exon 9 A/A 3 (0.6) 3 (0.6) 1.25 (0.25–6.34) 0.78
G/A + A/A 44 (7.9) 57 (11.1) 1.50 (0.98–2.28) 0.06
A allele freq. 0.042 0.058
Arg399Gln G/G 226 (40.4) 218 (41.0) 1.00 reference
rs25487 G/A 259 (46.2) 248 (46.6) 0.97 (0.75–1.26) 0.83
Exon 10 A/A 75 (13.4) 66 (12.4) 0.94 (0.64–1.39) 0.76
A allele freq. 0.365 0.357
Gln632Gln G/G 176 (31.4) 173 (32.2) 1.00 reference
rs3547 G/A 275 (49.0) 268 (49.9) 0.94 (0.72–1.24) 0.67
Exon 17 A/A 110 (19.6) 96 (17.8) 0.87 (0.61–1.23) 0.43
A allele freq. 0.441 0.428
EX17-123 -/- 492 (89.5) 448 (88.4) 1.00 reference
rs3213401 -/+ 55 (10.0) 56 (11.0) 1.18 (0.79–1.76) 0.43
3'UTR +/+ 3 (0.5) 3 (0.6) 0.78 (0.15–4.09) 0.77
-/+ plus +/+ 58 (10.5) 59 (11.6) 1.15 (0.78–1.70) 0.48
+ allele freq. 0.055 0.061
EX17-127 G/G 337 (64.1) 320 (65.6) 1.00
rs2682558 G/A 162 (30.8) 142 (29.1) 0.91 (0.69–1.20) 0.48
3'UTR A/A 27 (5.1) 26 (5.3) 1.13 (0.64–1.99) 0.68
A allele freq. 0.205 0.199
* Polymorphisms included name, dbSNP reference number and its location in XRCC1 gene.
aOR = odds ratio adjusted for subject's age, gender, smoking, occupational exposure and family history
-= wildtype without insertion, + = variant with insertion of GGGAATC
Table 2: The association between the 14 XRCC1 polymorphisms and bladder cancer risk (Continued)BMC Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2156/8/13
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This study was potentially limited by selection bias since
both community and hospital controls were included.
Although there were differences in the genotype distribu-
tions of one polymorphism significant at the 5% level, we
believe it unlikely that use of these two control groups
influenced the results. Recall bias for smoking, occupa-
tional exposure and family history cannot be excluded.
Our results must be interpreted cautiously bearing in
mind multiple testing as 14 XRCC1 polymorphisms were
selected. However, these tests are highly correlated since
numbers of polymorphisms were in almost perfect LD.
Exposure to tobacco smoke or to the occupational risk fac-
tors studied causes damage to DNA, and these exposures
have been shown to increase the risk of bladder cancer.
Exposure to these chemicals in an individual with an inef-
ficient DNA repair mechanism might be expected to ele-
vate risk more substantially. We therefore tested the
hypothesis that the joint effect on risk of exposure and
genotype was greater than multiplicative (gene-environ-
ment interaction). Stratified analysis by smoking and
chemical exposure did not show any significant gene envi-
ronment interaction. Interestingly, the 280His variant
allele seemed to have a greater influence on bladder can-
cer risk particularly among current smokers (adjusted OR
[95%CI], 2.51 [0.87–7.31], p = 0.09) but the likelihood
ratio test for interaction was not significant (p = 0.45). A
few other studies have investigated interactions between
XRCC1 polymorphisms and smoking on bladder cancer
risk [16,23,24]. None has shown evidence of interaction,
although it should be borne in mind that most studies to
date, including our own, only have sufficient power to
detect strong interactions.
Conclusion
This study provides no evidence of an association between
polymorphisms in XRCC1 and bladder cancer risk. How-
ever, although the study is relatively large (547 cases and
579 controls), there is limited power to detect the associ-
ation for low frequency variants such as Arg280His, and
the data are consistent with a modestly increased risk for
carriers of the variant allele.
Methods
Study population
A detailed description of the study population and design
has been given elsewhere [21]. In brief, 547 cases of blad-
der transitional cell carcinoma (TCC) were recruited from
August 2002 to April 2004 at our institution in Leeds, UK,
after obtaining ethical approval from the Leeds (East)
Local Research Ethical Committee. Cancer-free controls
(n = 579) were recruited from the community from 1997
to 2000 (n = 227) as part of a previous colorectal cancer
study [25] and from the hospital otolaryngology and oph-
Table 4: Estimated XRCC1 haplotype frequencies in cases and controls
Arg194Trp Arg280His Arg399Gln Controls haplotype (%) Cases haplotype (%)
C G G 52.9 52.6
C G A 36.9 36.1
C A G 4.2 5.5
T G G 6.0 5.8
Total 100.0 100.0
Table 3: Stratified analysis by smoking and occupational status for XRCC1 Arg280His polymorphism
Exposure status Genotypes Control (n) Cases (n) Crude OR (95%CI) Adjusted OR (95%CI) P value
Smoking Non-smoker G/G 174 103 1.00 1.00
G/A + A/A 16 12 1.27 (0.58–2.78) 1.13 (0.50–2.56) 0.77
Ex smoker G/G 253 244 1.00 1.00
G/A + A/A 23 29 1.31 (0.74–2.32) 1.30 (0.73–2.33) 0.38
Current smoker G/G 89 108 1.00 1.00
G/A + A/A 5 16 2.64 (0.93–7.48) 2.52 (0.87–7.31) 0.09
Occupation No occupational exp G/G 429 327 1.00 1.00
G/A + A/A 35 43 1.61 (1.01–2.58) 1.55 (0.96–2.51) 0.07
Occupational exp G/G 87 129 1.00 1.00
G/A + A/A 9 14 1.05 (0.43–2.53) 1.03 (0.42–2.54) 0.95
* Adjusted OR for subject's age, gender, smoking, occupational exposure and family historyBMC Genetics 2007, 8:13 http://www.biomedcentral.com/1471-2156/8/13
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thalmology departments in 2002 to 2004 (n = 352) in the
same region. The participation rate for cases and controls
were 99% and 80% respectively.
Each subject donated a blood sample and completed a
structured health questionnaire regarding smoking, occu-
pational and family history. Occupational exposure was
defined as participating in occupations involving rubber/
plastics industries, laboratories, printing, paints, dyes or
diesel fumes.
Genotyping
We selected XRCC1 polymorphisms based on potential
function from the public domain of the Environmental
Genome Project (EGP) via the National Centre for Biotech-
nology Information[26]. XRCC1 polymorphisms with
allele frequencies of more than 1% located in the promoter
region (up to 1000 bases upstream of the gene), 5'and 3'
untranslated regions (UTR), exons, and intronic regions
with known or potential splicing effects (within 100 bases
up and downstream of exons) were selected (Table 1).
Genotyping was performed using the allelic discrimination
5' nuclease assay (Taqman) without prior knowledge of the
subject's clinical status, as previously described [21]. Prim-
ers and probes are listed in Table 5. As a quality control
measure, 5% of the samples (n = 57) were regenotyped
with 100% concordance.
Statistical analysis
All data were analyzed using Stata Statistical Software
Release 8 (Stata Corporation, 2003, College Station,
Texas). Hardy-Weinberg equilibrium analyses were per-
formed to compare observed and expected genotype fre-
quencies using a chi-squared goodness-of-fit test. The
linkage disequilibrium (LD) between polymorphisms was
estimated by pairwise Lewontin's D' and r2 using the
STATA pwld function [27]. The odds ratio (OR) and 95%
confidence interval (CI) for bladder cancer associated
with each genotype were calculated using logistic regres-
sion analysis, both without adjustment and adjusted for
established bladder cancer risk factors (age, sex, cigarette
smoking, occupational exposure and family history).
Haplotypes were estimated by the Expectation Maximiza-
tion (EM) algorithm [28] and their frequencies in cases
and controls compared using a likelihood ratio test with a
permutation procedure to obtain empirical p-values as
implemented in EHPLUS [29]. With a sample size of 547
cases and 579 controls, we had an 90%, 78% and 55%
power to detect an OR of 1.50 for carriage of the minor
allele of frequency 0.20, 0.10 and 0.05 respectively (2
sided, p = 0.05). Gene-environment interaction was
assessed by stratification of subjects based on smoking
status and occupational exposure, and p values are calcu-
lated based on the likelihood-ratio test, comparing mod-
els with and without an interaction term.
Authors' contributions
SCS recruited the cases and the majority of the controls,
co-ordinated the genotyping, performed the main statisti-
cal analyses and interpretation of results, drafted the man-
uscript.
JHB participated in the design of the study, advised on
and carried out some of the statistical analyses and inter-
preted the results, and helped to draft and redraft the
manuscript.
ABP gave clinical advice on patients, participated in the
design of the study and critically appraised the manu-
script.
DTB helped in the conception of the study, the interpreta-
tion of the results and redrafting of the manuscript.
Table 5: List of primers and probes for 14 XRCC1 polymorphisms
Polymorphisms Forward primers Reverse primers VIC probes FAM probes
rs2682586 GTCCCAGATTGAGAGAGAGAGAGAT CCCGTTCACCTTGAGGACTTG CTGAAGGCTCTCTCTCT TGAAGGCTCTTTCTCT
rs2682585 CTCCCCGTAGGGTGAATGTG CTGGTCCCCAGCTTTTATAGGAA CAGACCCGCCCCTC CAGACCCACCCCTC
rs3213239 CACCACCCTGTTTTCTCACCTT AGGCCCAACTCCGTCTTG CAATGGGCCGGCCGT CAAACAACAATGGGCCGT
rs3213245 CGCGCTTGCGCACTTTAG GCCAGAAGGATGAGGTAGAGTATG CCCGCTCCCTCCCA CCGCCCCCTCCCA
rs2307187 CCCCATACTCTACCTCATCCTTCTG GCTGCAGGACACGACATG CCGGCATGTCAACGT TCCGGCATATCAACGT
rs25496 TGGGAATGATGGCTCAGCTTT CCTGCTTACCTCATAGTCTTGCT ACTGCCCACCAGCAC TGCCCGCCAGCAC
rs1799782 AGGATGAGAGCGCCAACTC ACTCAGGACCCACGTTGTC TTGTTGATCCGGCTGAA TTGTTGATCCAGCTGAA
rs1799780 CCATAGATAGGAGTGAAAGGGTCTTG GCTGTGACTATGAAGGGAGAAAGTG CAGGATGAGAGGGCTGA CAGGATGAGAAGGCTGA
rs915927 TCCACTTTCTCCCTTCATAGTCACA AGGGTAGCAGCTGCATAGC CCAGCGACCCAGCAG CCAGCGACCCGGCAG
rs25489 CCAGTGGTGCTAACCTAATCTACTCT GCTCGGGCAGGGACTG CTCCAACTCGTACCCC TCCAACTCATACCCC
rs25487 GTGGGTGCTGGACTGTCA GCAGGGTTGGCGTGTGA CCTCCCGGAGGTAA CCCTCCCAGAGGTAA
rs3213401 GAGTTGGTTCTCATCCAAGA AAGATACAGGTGTGGCTCAG * *
rs2682558 CCTTATCCCTGTGTTGGCAAGAG GGCTCAGAGGGCCAGAAAA CAGATTCCCAGTTCCCT CAGATTTCCAGTTCCCT
rs3547 TGTGTGTGTGTGTGTGTATAGCA GCAGAAGTTACTTCCTCACCATCTC CCGCAGGCCTGAAG CCGCAAGCCTGAAG
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